BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy

    loading  Checking for direct PDF access through Ovid


We present the case of a 66-year-old man with castration-resistant prostate cancer, with an increasing prostate-specific antigen level, and a progressive disease during 177Lu-PSMA radionuclide therapy. Because the patient had a BRCA2 mutation, poly-ADP ribose polymerase inhibitor therapy was started. The patient showed a dramatic subjective and biological response to this therapy with a progression-free survival of 5 months.

    loading  Loading Related Articles